Theragnostics inks AstraZeneca agreement

AuntMinnie.com staff writers

Sep 4, 2019

Molecular radiotherapy developer Theragnostics said it has signed an intellectual property agreement with AstraZeneca.

The agreement allows Theragnostics to develop radiotherapy based on radionuclide-labeled poly (ADP-ribose) polymerase (PARP) inhibitors, a class of oncology drugs that block the PARP enzyme, which cancer cells use in response to DNA damage.

Breast Cancer3 400

ASTRO: Shorter radiation course safe for breast reconstruction

October 2, 2024

ASTRO: Timing key to adding immunotherapy to chemoradiation

October 1, 2024

ASTRO: Black patients voice distrust in medical research

September 30, 2024

Prostate Imaging

ASTRO: IMRT and proton therapy equally effective for prostate cancer

September 30, 2024

ASTRO: Shorter radiation course safe for breast reconstruction

By Amerigo Allegretto

Research presented at the ASTRO annual meeting shows that a shorter course of postmastectomy radiation combined with breast reconstruction is safe.

October 2, 2024

Breast Cancer3 400

ASTRO: Timing key to adding immunotherapy to chemoradiation

By Amerigo Allegretto

Timing may be key when adding immunotherapy to chemoradiation for lung cancer treatment.

October 1, 2024

ASTRO: Black patients voice distrust in medical research

Spiritual beliefs and a distrust of clinical research may partly explain why Black patients choose not to participate in cancer trials.

September 30, 2024

ASTRO: IMRT and proton therapy equally effective for prostate cancer

Intensity-modulated radiation therapy (IMRT) and proton therapy offer equally high quality of life and tumor control for people with prostate cancer.

September 30, 2024

Prostate Imaging

ASTRO: Lu-177 dotatate shows promise for treating meningioma patients

By Kate Madden Yee

A radiopharmaceutical therapy that lengthens progression-free survival for patients with neuroendocrine cancer could help treat meningioma sufferers.

September 30, 2024

ASTRO: Brain cancer patients treated by radiation recoup cognitive function

By Kate Madden Yee

Patients with brain metastases who experience cognitive side effects after radiation therapy appear to eventually regain cognitive function.

September 30, 2024

Brain Puzzle Dementia

Bone marrow disorders associated with SARs in Lutathera patients

Pretreatment bone marrow disorders may predict which patients are at risk for severe adverse reactions (SARs) when treated with lutetium-177 DOTATATE.

July 15, 2024

2024 07 11 Sa Rs Patients Lu 177 Dotatate Voter

The rise of theranostics: Part 5 -- Advice from center administrators

Want to launch theranostics at your hospital and cancer center? An SNMMI 2024 session provided key planning steps.

July 12, 2024

Nuclear medicine technologist and theranostics practice administrator Dmitry Beyder (left) and Vikas Prasad, MD, PhD (right), lead the theranostics center at Barnes-Jewish Hospital/Washington University in Saint Louis, MO. Image courtesy of Washington University.

Risk factor for blood disorders identified in PRRT patients

Researchers have identified a risk factor that may be involved in potentially fatal blood disorders in patients undergoing peptide receptor radionuclide therapy (PRRT).

July 12, 2024

ASTRO chair responds to proposed cuts in 2024 MPFS

By AuntMinnie.com staff writers

ASTRO has issued a statement from Jeff Michalski, MD, in response to continued reimbursement declines in the proposed 2025 MPFS.

July 11, 2024

Capitol Hill Government 400

ASTRO lobbies for new radiation therapy payment bill

AuntMinnie.com spoke with Casey Chollet-Lipscomb, MD, who joined radiation oncologists from around the U.S. to lobby for a new payment model for radiation therapy.

May 21, 2024

AI chatbots deemed ‘empathetic’ to cancer patients

AI chatbots can generate high-quality, empathetic, and readable responses to cancer patients' questions compared with physicians.

May 16, 2024

Page 1 of 462